期刊文献+

达托霉素透皮制剂的制备及效果评价 被引量:4

Preparation and quality analysis of daptomycin transdermal delivery system
下载PDF
导出
摘要 目的制备达托霉素软膏,并对其进行制剂学和药效学初步评价。方法采用乳化法制备O/W型和W/O型两种达托霉素软膏。通过考察物理性状、体外透皮渗透率、体内外药效学及抗细菌生物被膜,确定较优处方并初步建立达托霉素软膏剂透皮实验方法。结果 O/W型达托霉素软膏的累积渗透率在8h时达53.35%,透皮渗透量为78.30μg/cm2。与W/O型达托霉素软膏相比具有更强的抑菌作用。结论 O/W型达托霉素软膏制备工艺简单,制剂稳定性好,抑菌快速强效。 Objective To investigate the preparation and quality analysis of daptomycin ointment with good bacteriostasis efficacy. Methods Two types of daptomycin ointment were prepare by O/W and W/O emulsion process. The optimized prescription of daptomycin ointment was obtained and evaluated by a series of factors including physical behaviors, transdermal experiments in vitro, transdermal antibacterial experiments in vitro, antibiofilm in vitro and pharmacodynamics experiment. Result The cumulative release rate of O/W daptomycin ointment was 53.35% after 8 hours. The O/W ointment of daptomycin has shown priority over the W/O formulation in antibacterial effect. Conclusion The results demonstrated the advantages of the O/W daptomycin ointment: simple preparation process, good stability, fast and potent antibacterial activity.
机构地区 西南大学药学院
出处 《中国抗生素杂志》 CAS CSCD 北大核心 2013年第2期130-134,共5页 Chinese Journal of Antibiotics
基金 "重大新药创制"科技重大专项(2010ZX09401-306-1-4)
关键词 达托霉素 软膏剂 透皮制剂 生物被膜 Daptomycin Ointment Transdermal delivery system Biofilm
  • 相关文献

参考文献8

二级参考文献37

  • 1尤静,穆国平,范涛,傅经国,葛志强.气相色谱法测定脂质体中溶剂氯仿的残留量[J].中国药物与临床,2006,6(2):130-131. 被引量:4
  • 2Grundmann HM, Aires-de-Sousa M Boyce J, et al. Emergence and resurgence of meticillin-resistant Staphylococcus aureus as a public-health threat. [ J ]. Lancet, 2006,368 ( 9538 ) : 874 - 885.
  • 3Daum RS, Seal JB. Evolving antimicrobial chemotherapy for Staphylococcus aureus infections: Our backs to the wall. [ J ]. Crit Care Med, 2001,29(4 Suppl) :N92 -96.
  • 4Zetola N, Francis JS, Nuermberger EL, et al. Communityacquired meticinin-resistant Staphylococcus aureus: an emerging threat.[J]. Lancet Infect Dis, 2006,6(12) :753 -755.
  • 5Goldstein E J, Citron DM, Warren YA, et al. Virulence characteristics of community-associated Staphylococcus aureus and in vitro activities of moxifloxaein alone and in combination against community-associated and heahbcare-associated meticillinresistant and -susceptible S. aureus. [ J ]. J Med Microbiol, 2008,57 (4) :452 - 456.
  • 6Mahezou HC, Giamarellou H. Community-acquired methicillin- resistant Staphylococcus aureus infections [ J ]. Int J Antimicrob Agents, 2006,27(2) :87 -96.
  • 7Li M, Diep BA, Villaruz AE, et al. Evolution of virulence in epidemic community-associated methicillin-resistaut Staphylococcus aareus [ J ]. Pruc Natl Acad Sci U S A, 2009,106(14) :5883 -5888.
  • 8Ayliffe GAJ. The Progressive intercontinental spread of methicillin-resistant Staphylococcus aureus [ J]. Clin Infect Dis, 1997,24(1) :S74 - S79.
  • 9Rihn JA, Michaels MG, Harner CD. Community-acquired methicillin-resistant Staphylococcus aureus: An emerging problem in the athletic population[ J ]. Am J Sports Med, 2005, 33:1924-1929.
  • 10King MD, Humphrey BJ, Wang YF, et al. Emergence of community-acquired methicillin-resistant Staphylococcus aureus USA 300 clone as the predominant cause of skin and soft-tissue infections[ J]. Ann Intern Med, 2006,144(5 ) :309 - 317.

共引文献14

同被引文献34

  • 1Bell J M, Turnidge J D. SENTRY APAC Participants: high prevalence of oxacillin-resistant Staphylococcus aureus isolates from hospitalized patients in asia-pacific and south africa: results from sentry antirnicrobial surveillance program, 1998-1999[J]. Antimicrob Agents Chemother, 2002, 46(3): 879-881.
  • 2Stefani S, Varaldo P E. Epidemiology of methieillin-resistant staphylococci in Europe[J]. Clin Microbiol Infect, 2003, 9(12): 1179-1186.
  • 3Tally F P, DeBruin M F. Development of daptomycin for Gram-postive infections[J]. JAntimicrob Chemother, 2000, 46(4): 523-526.
  • 4Steenbergen J N, Alder J, Thome G M, et al. Daptomycin: a lipopeptide antibiotic for the treatment of serious Gram- postive infections[J]. JAntimicrob Chemother, 2005, 55(3): 283-288.
  • 5Zanger P, Holzer J, Schleucher R, et al. Severity of Staphylococcus aureus infection of the skin is associated with inducibility of human 13-defensin 3 but not human 13-defensin 2 [J]. lnfect lmmun, 2010, 78(7): 3112-3117.
  • 6Eckmann C, Dryden M. Treatment of complicated skin and soft-tissue infections caused by resistant bacteria: value of linezolid, tigecycline, daptomycin and vancomycin[J]. Eur J MedRes, 2010, 15(12): 554-563.
  • 7Godin B, Touitou E, Rubinstein E, et al. A new approach for treatment of deep skin infections by an ethosomal antibiotic preparation: an in vivo study[J]. J Antimicrob Chemother, 2005, 55(6):989-994.
  • 8Schafer-Korting M, Mehnert W, Korting H C. Lipid nanoparticles for improved topical application of drug for skin disease[J]. Adv Drug Deliv Rev, 2007, 59(6):427-443.
  • 9Garg B J, Saraswat A, Bhatia A, et al. Topical treatment in vitiligo and the potential uses of new drug delivery systems[J], lndian J DermatoI Venereol Leprol, 2010, 76(3):231-238.
  • 10Touitou E, Dayan N, Bergelson L, et al. Ethosomes-novelvesicular carriers for enhanced delivery: characterization and skin penetration properties[J]. J Control Rel, 2000, 65(3): 403-418.

引证文献4

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部